Piper Sees 'Re-Birth' For Amarin Shares In 2021, Keeps $19 Price Target
January 08, 2021 at 11:21 AM EST
Heading into early 2021, Amarin shares continue to be "repressed and undervalued" ahead of a key binary event of European approval of Vascepa, Piper Sandler analyst Yasmeen Rahimi tells investors in a research note.